Last reviewed · How we verify
NCT04077983
Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma
Phase 2 trial testing combined therapy using nab-paclitaxel and gemcitabine chemotherapy in Cholangiocarcinoma, Intrahepatic in 40 participants. Status unknown.
1 September 2020
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 1 September 2019 |
| Primary completion | 1 September 2020 |
| Estimated completion | 1 September 2022 |
Drugs / interventions tested
- combined therapy using nab-paclitaxel and gemcitabine chemotherapy — full drug profile →
Conditions studied
- Cholangiocarcinoma, Intrahepatic — all drugs for Cholangiocarcinoma, Intrahepatic →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 18 to 75, any sex, with Cholangiocarcinoma, Intrahepatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this phase 2 study, we aim to evaluate the effects and safety of combined therapy using nab-paclitaxel and gemcitabine chemotherapy for patients after radical resection of Intrahepatic Cholangiocarcinoma
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.
Chen X, Du J, Huang J, Zeng Y, et al · · 2022 · cited 23× · PMID 35836758 · DOI 10.14218/jcth.2021.00250 -
Recent advancements in systemic therapy for biliary tract cancers: a literature review.
Hussain MM, Qammar S, Wang JM, Zhai AQ, et al · · 2025 · PMID 41220768 · DOI 10.21037/jgo-2025-83
Verify or expand the search:
- PubMed search for NCT04077983
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cholangiocarcinoma, Intrahepatic
Currently open trials in the same condition.
- NCT05210322 — Percutaneous Cholangiopancreatoscopy Registry · active not recruiting
- NCT04634058 — PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed A · Phase 2 · active not recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04077983 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 4 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04077983.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing